Tovetumab

Tovetumab is a fully human monoclonal antibody developed by AstraZeneca that targets platelet-derived growth factor receptor alpha (PDGFRA), a tyrosine kinase receptor implicated in tumor growth and angiogenesis. By binding specifically to PDGFRA, tovetumab blocks the interaction of PDGF ligands with the receptor, thereby inhibiting downstream signaling pathways such as PI3K/AKT and MAPK/ERK that promote cell proliferation and survival. Tovetumab was investigated primarily for cancers characterized by high PDGFRA expression, including glioblastoma and non-small cell lung cancer (NSCLC). Despite initial promise in preclinical studies, clinical trials demonstrated minimal efficacy in reducing tumor growth. As a result, development of tovetumab was discontinued around 2013 due to poor clinical performance. It is now available only for research purposes[6][8].

Brand names

tovetumab

Other names

MEDI-575MEDI575MEDI 575anti-PDGFRα monoclonal antibody MEDI-575